Olympia nct02032823
WebNICE在提出建议时考虑了奥拉帕尼制造商阿斯利康的证据，即来自3期OlympiA试验（NCT02032823）的临床试验证据。这项随机试验比较了奥拉帕尼与安慰剂在化疗、手术和放疗后患有BRCA突变、HER2阴性、高危早期乳腺癌的患者。 主要终点是侵袭性无病生存 … Web08. jun 2024. · Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the findings of OlympiA (NCT02032823), a randomized, double-blind, Phase III trial evaluating adjuvant olaparib after neoadjuvant chemotherapy in patients with germline BRCA1/2 mutations (gBRCAm) and high-risk HER2-negative early breast cancer. …
Olympia nct02032823
Did you know?
Web03. jun 2024. · Destacado como Late Breaking Abstract 1 no ASCO 2024, o estudo OlympiA mostrou que a adição de 1 ano do inibidor de PARP olaparibe após a conclusão do tratamento multimodal com quimioterapia (neo)adjuvante padrão, cirurgia e radioterapia, se indicada, melhorou significativamente a sobrevida livre de doença invasiva (IDFS) e a … Web12. mar 2024. · OlympiA (NCT02032823), un estudio internacional aleatorizado (1:1), doble ciego, controlado con placebo de 1836 pacientes con cáncer de mama temprano de alto riesgo gBRCAm HER2 negativo que completaron el tratamiento local definitivo y quimioterapia neoadyuvante o adyuvante, recibió la aprobación.
Web08. apr 2024. · More recently, the FDA also granted olaparib approval for adjuvant treatment of BRCA-mutated, HER2-negative high-risk early breast cancer, previously treated with chemotherapy in neoadjuvant or adjuvant scenarios, based on the OlympiA (NCT02032823) clinical trial . OlympiA was a phase III, double-blinded clinical trial with … Web18. mar 2024. · Approval was based on OlympiA (NCT02032823), a randomised (1:1), double-blind, placebo-controlled, international study of 1836 patients with germline …
Web10. jan 2014. · NCT02032823 Other Study ID Numbers: D081CC00006 NSABP B-55 ( Other Identifier: NSABP ) BIG 6-13 ( Other Identifier: Breast International Group ) First … Web16. mar 2024. · OlympiA. OlympiA is a Phase III, double-blind, parallel group, placebo-controlled, multicenter trial testing the efficacy and safety of LYNPARZA tablets versus placebo as adjuvant treatment in patients with gBRCAm high-risk HER2-negative early breast cancer, who have completed definitive local treatment and neoadjuvant or …
Web在3期OlympiA试验（NCT02032823）中，与安慰剂相比，Lynparza辅助治疗显著延长了无侵袭性疾病生存期（IDFS）和总生存期（OS）。 乳腺癌是全球诊断最多的 ...
Web10. jun 2024. · Eine erste Zwischenanalyse der OlympiA-Studie zeigt eine signifikante Verbesserung des invasiven krankheitsfreien Überlebens bei Patientinnen mit HER2-negativem, BRCA1/2-Keimbahnmutiertem primärem Brustkrebs mit hohem Risiko nach 1 Jahr adjuvanter Behandlung mit dem PARP-Inhibitor Olaparib. boys coloured suitsWeb11. mar 2024. · OlympiA. OlympiA is a Phase III, double-blind, parallel group, placebo-controlled, multicentre trial testing the efficacy and safety of Lynparza tablets versus … boys collared sweatersWeb25. maj 2024. · The definitive large adjuvant trial testing olaparib in carriers of germline BRCA1/2 mutations, OlympiA (NCT02032823), recently reported positive results in a press release; details will be ... boys colouring in pagesWeb19. mar 2024. · The approval is based on data from the phase 3 OlympiA trial (NCT02032823), in which participants who have previously received chemotherapy treated with olaparib either before or after surgery demonstrated a 42% improvement in invasive disease-free survival (iDFS) compared with placebo (HR, 0.58; 95% CI, 0.46-0.74; P … boys colouring pages to printWeb08. jun 2024. · Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, speaks on the findings of OlympiA (NCT02032823), a randomized, double-blind, Phase III trial … boys columbia fleece jacket wave graphiteWeb26. sep 2014. · Three Phase III trials of olaparib monotherapy have been initiated in BC pts with a gBRCAm: OlympiA (NCT02032823), Neo-Olympia (D081EC00005), OlympiAD … gwinnett technical college veteransWebCAMBRIDGE, England -- Businesswire -- AstraZeneca today presented results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with Lynparza (olaparib) maintenance therapy following platinum-based chemotherapy. gwinnett technical college summer 2023